PRIMARY STUDY
Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma.
Key Findings: The study shows the involvement of CB2 receptor agonism via WIN 55,212–2 inhibits renal cell carcinoma in vitro.
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): Canada, Poland
Year of Pub: 2018
Cannabinoids Studied: AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
Route of Administration: In vitro
Citation: Khan MI, et al. Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC Cancer. 2018; 18:583. doi: 10.1186/s12885-018-4496-1
Authors: Khan MI, Sobocińska AA, Brodaczewska KK, Zielniok K, Gajewska M, Kieda C, Czarnecka AM, Szczylik C
